Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis.
Collecting a sufficient number of T-cells is a critical first step in the production of chimeric antigen receptor (CAR)-T cells. Herein, we report a successful implementation of anticoagulation with combined heparin and acid citrate dextrose solution A (ACD-A) for the continuous mononuclear cell (CMNC) protocol on the Spectra Optia in a 20-month-old, 7.5 kg patient with refractory acute lymphoblastic leukemia for manufacture of tisagenlecleucel, a CAR-T cell therapy. Combined heparin/ACD-A was used following clotting issues when ACD-A was used alone during initial CMNC collections. To our knowledge, this is the first reported case in pediatrics of combined heparin/ACD-A anticoagulation with the Spectra Optia CMNC protocol.
J Clin Apher
Anticoagulants; Child; Citric Acid; Glucose; Heparin; Humans; Immunotherapy, Adoptive; Infant; Leukapheresis; Leukocytes, Mononuclear; Pediatrics; T-Lymphocytes
anticoagulation; chimeric antigen receptor-T cells; continuous mononuclear cell collection; pediatric apheresis
DeSimone, Robert A.; Myers, Gary D.; Guest, Erin M.; and Shi, Patricia A., "Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis." (2019). Manuscripts, Articles, Book Chapters and Other Papers. 1365.